How a brain messenger protein drives progression of Alzheimer's disease

by University of Utah Health Sciences

edited by Gaby Clark, reviewed by Robert Egan

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Alzheimer's disease is driven by a buildup of a toxic protein called Tau that kills neurons. As toxic Tau spreads to new regions of the brain, symptoms worsen and ultimately become fatal.

Now, researchers have discovered that, in mice, a brain protein called Arc helps spread Tau from sick brain cells to healthy ones.

If therapies could be designed to target the spread, they could be a powerful tool to stop Alzheimer's disease from getting worse.

"I'm excited by the fact that we've identified a new way of potentially stopping the progression of Alzheimer's disease," says Jason Shepherd, Ph.D., professor of neurobiology at University of Utah Health and senior author of the study.

The results are published in Cell.

A deadly hitchhiker

By studying a mouse model of Alzheimer's disease with and without Arc protein, the research team found that Arc is needed for toxic Tau to spread.

Arc normally serves as a vital messenger between brain cells: It wraps itself up in a microscopic bubble, called an extracellular vesicle or EV, that floats from one neuron to the next, carrying important information. But toxic Tau can stick to Arc to hitch a ride from a diseased neuron to a healthy one.

All brain cells, healthy and unhealthy, contain Tau. But in Alzheimer's disease, Tau starts clumping together into massive, sticky tangles inside neurons, ultimately killing the cells. Mitali Tyagi, Ph.D., postdoctoral research associate at Washington University in St. Louis and first author on the paper, who did the research while a neuroscience graduate student in the Shepherd Lab at U of U Health, compares Tau tangles to "glue monsters."

"They glue together and block transportation within the neuron," Tyagi explains. "But they can break down into smaller glue monsters, called Tau seeds, which can then get transferred to a new neuron. And once this Tau seed comes into contact with healthy Tau, it is able to corrupt it. So, the pathology starts all over again in a healthy neuron."

In a mouse model of Alzheimer's disease, the researchers found EVs containing both Arc and "sticky" Tau within the brain. These tiny bubbles of Arc and Tau could infect healthy cells and start new Tau tangles.

But in Alzheimer's model mice that lacked Arc, their brain EVs contained barely any Tau and could no longer spread the disease to new cells. "When we removed Arc, we saw that the transfer of Tau was severely, severely reduced," Tyagi says. "It was almost gone."

A double-edged sword

While it may seem like blocking Arc could be a therapeutic solution for Alzheimer's, the protein may also play a protective role in the early stages of the disease. By getting rid of excess toxic Tau, Arc seems to help sick cells stay alive longer.

The researchers found that in mice that lack Arc and thus can't eject toxic Tau from sick cells, those sick cells die faster.

"When Arc is absent, Tau becomes trapped inside neurons and accumulates to toxic levels. When Arc is present, Tau can be released in extracellular vesicles. While this helps reduce Tau buildup within the original neuron, the released Tau can be taken up by neighboring healthy neurons, promoting the spread of pathology," Tyagi says.

This suggests that stopping toxic Tau from entering healthy cells could be a more effective therapeutic strategy than preventing Tau release from sick cells.

Future directions

The team found that, like in mice, human brain tissue also contains EVs that include both Arc and Tau, suggesting that Tau likely spreads in a similar way in people. However, the researchers caution that more work is needed before a therapy is possible.

"Most of the work we've been doing is in mice, not in humans," Shepherd says. "We have some clues that whatever is happening in these mice could also be happening in humans, but we don't know that yet. And we're far away from saying that we're developing a treatment for anything. But it could open new avenues to get to that point."

The team is especially excited by the possibility that future therapies might block toxic Tau-containing EVs "midflight," after they've been ejected from sick cells but before they can infect healthy ones. Such therapies wouldn't repair existing damage to the brain but might prevent the disease from progressing.

"If we could target these particular EVs, that would be a really useful therapy strategy," Shepherd says. "For someone with early-onset Alzheimer's or dementia, if we could stop the spread, then we could prevent further damage and cognitive decline."

Publication details

Arc mediates intercellular tau transmission via extracellular vesicles., Cell (2026). DOI: 10.1016/j.cell.2026.06.008. www.cell.com/cell/fulltext/S0092-8674(26)00695-1

Journal information: Cell

Key medical concepts

Alzheimer's DiseaseExtracellular VesiclesNeurons

Clinical categories

Neurology Provided by University of Utah Health Sciences Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: How a brain messenger protein drives progression of Alzheimer's disease (2026, June 26) retrieved 26 June 2026 from https://medicalxpress.com/news/2026-06-brain-messenger-protein-alzheimer-disease.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.